Dermata Therapeutics, Inc. develops dermatologic solutions and is repositioning its business around direct-to-consumer skincare under the Tome brand. Company updates center on OTC skincare concepts, including once-weekly acne and skin renewal products that use the company's Bioneedle and Spongilla technologies, as well as intellectual-property developments for Bioneedle Delivery System applications involving dermal fillers, botulinum toxin and hyperhidrosis.
Recurring Dermata news also includes financial results, private placements and at-the-market equity activity, along with management, marketing and board developments tied to its shift from pharmaceutical development toward consumer skincare products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Dermata Therapeutics (NASDAQ:DRMA, DRMAW) announced significant progress in its development of DMT310, a treatment for moderate-to-severe acne. The FDA has acknowledged that Dermata's Chemistry, Manufacturing, and Controls (CMC) procedures are adequate for initiating Phase 3 studies. Furthermore, the company submitted an end of Phase 2 meeting package to discuss clinical requirements with the FDA. Dermata anticipates receiving feedback on this package by the end of June 2023 and plans to begin Phase 3 trials in the second half of 2023. Upon successful completion of these trials, the company may proceed with a new drug application for DMT310.